Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Real-time Estimate Cboe BZX  -  04:06 2022-11-30 pm EST
307.94 USD   +5.67%
04:00pWall Street ends sharply higher after Powell comments
RE
03:19pEisai, Biogen Alzheimer's drug could be available to some next year
RE
02:27pWall Street rallies after Powell eyes slower rate hikes
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Needham Adjusts Biogen's Price Target to $250 From $262, Reiterates Buy Rating

07/21/2022 | 09:16am EST


ę MT Newswires 2022
All news about BIOGEN INC.
04:00pWall Street ends sharply higher after Powell comments
RE
03:19pEisai, Biogen Alzheimer's drug could be available to some next year
RE
02:27pWall Street rallies after Powell eyes slower rate hikes
RE
02:15pWall Street rises after Powell eyes slower rate hikes
RE
12:34pDow dips ahead of Powell speech; Nasdaq kept afloat by growth stocks
RE
11:34aGlobal markets live: Apple, Tesla, Boeing, HP, Intuit...
MS
10:31aTrending: Eisai/Biogen Alzheimer's Drug Shows Positive Results
DJ
10:13aAll eyes on Powell
MS
10:03aStifel Adjusts Price Target on Biogen to $331 From $299, Maintains Buy Rating
MT
10:01aJefferies Adjusts Price Target on Biogen to $350 From $325, Maintains Buy Rating
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 067 M - -
Net income 2022 2 904 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,3x
Yield 2022 -
Capitalization 41 963 M 41 963 M -
EV / Sales 2022 4,19x
EV / Sales 2023 4,14x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 291,41 $
Average target price 315,77 $
Spread / Average Target 8,36%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP